Targeting a specific protein to improve treatment for certain types of leukemia
Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)
This study is looking at new ways to treat a tough type of leukemia called Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by focusing on a protein called CDK6, which helps cancer cells grow, to see if targeting it can make treatments work better and help prevent the cancer from coming back, and patients may have the chance to participate in trials to test these new approaches.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10867341 on NIH RePORTER |
What this research studies
This research focuses on Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and Ph1-like B-ALL, which are high-risk forms of leukemia in adults. The study aims to investigate the role of CDK6, a protein that is crucial for the growth of these cancer cells, and how targeting it can improve treatment outcomes. By using innovative techniques to degrade CDK6 specifically, the researchers hope to enhance the effectiveness of existing therapies and reduce the chances of disease relapse. Patients may be involved in trials assessing the safety and efficacy of these new treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Philadelphia-positive acute lymphoblastic leukemia or Ph1-like B-ALL.
Not a fit: Patients with other types of leukemia or those who do not have Philadelphia-positive or Ph1-like characteristics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Ph+ ALL and Ph1-like B-ALL, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promising results in targeting CDK6 in similar leukemia types, indicating a potential for success with this approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Calabretta, Bruno — Thomas Jefferson University
- Study coordinator: Calabretta, Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.